DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020

Press/Media: Press / Media

PeriodNov 13 2020

Media coverage

19

Media coverage

  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletPR Newswire
    CountryUnited States
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletGlobal English (Middle East and North Africa Financial Network)
    CountryJordan
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletPR Newswire
    CountryUnited States
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletMorningstar.com
    CountryUnited States
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletFinanzen.net
    CountryGermany
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletYahoo! Finance
    CountryUnited States
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT CORPORATION : Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletMarketScreener.com
    CountryUnited States
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletMarket Newsdesk
    CountryUnited States
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletProfitQuotes.com
    CountryUnited States
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletFinanzen.ch
    CountrySwitzerland
    Date11/13/20
    PersonsEric J Lawitz
  • Title$DRRX DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletOTC Dynamics
    CountryCanada
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletBioSpace
    CountryUnited States
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletTickerTech.com
    CountryUnited States
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience(TM) 2020
    Media name/outletWFMZ-TV Online
    CountryUnited States
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletTullahoma News
    CountryUnited States
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletHerald Chronicle
    CountryUnited States
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletManchester Times
    CountryUnited States
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletCitizen Tribune
    CountryUnited States
    Date11/13/20
    PersonsEric J Lawitz
  • TitleDURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020
    Media name/outletElk Valley Times
    CountryUnited States
    Date11/13/20
    PersonsEric J Lawitz